The ZnT8 autoantibody is used to independently diagnose type 1 diabetes (T1D) and as a prediction factor in high-risk populations. This is the first report in Taiwan on the prevalence, diagnostic utility, and clinical characteristics of zinc transporter 8 autoantibody (ZnT8A) in children with T1D. We performed a retrospective analysis of 268 children (130 boys, 138 girls) newly diagnosed with T1D at three hospitals in North Taiwan from February 1994 to August 2021. ZnT8A was detected in 117 patients (43.7 %). The combined diagnostic rate of the four antibodies, including glutamic acid decarboxylase autoantibody (GADA), islet antigen 2 autoantibody (IA2A), insulin autoantibody (IAA), and ZnT8A, can reach 86.19 % while that of the original three antibodies is 84.3 %. IA2A (64.9 %) showed the highest positive rate, followed by GADA (64.2 %), ZnT8A (43.7 %), and IAA (22.0 %). Of the 268 patients, five (1.9 %) were only ZnT8A+. All antibodies were positive in 19 (7.1 %) people, whereas 37 others (13.8 %) had all antibodies negative. ZnT8A has the strongest relationship with IA2A. 5 patients had ZnT8A positive only. 5/(37 + 5) (about 12 %) T1D patients were diagnosed by ZnT8A testing. ZnT8A testing can diagnose up to 12 % more patients with T1D along with three other antibodies. Furthermore, since the ZnT8A titer decreased over time, it should be tested within six months of onset in Taiwanese patients with T1D.
19 September 2026 in Endocrinology, Diabetes & Metabolism
Introduction: This prospective study (NCT06283641) was the first real‐world, multicentre, post‐marketing surveillance of GLP‐1 receptor agonist liraglutide as an adjunct for weight management in adults with obesity in Taiwan. Methods: Data were collected from 14 sites at baseline, week 13 and week 26 (February 2024–January 2025). Safety and effectiveness outcomes, including adverse event (AE) incidence proportions (IPs) and body weight (BW) change, were investigated. Results: Among 259 adults, 61.0% were female (mean ± SD age 42.6 ± 11.3 years, BW 90.4 ± 17.6 kg, BMI 33.0 ± 4.7 kg/m 2 ). Dyslipidaemia (38.2%), hypertension (26.3%), and diabetes (21.2%) were common. Mean daily and maximum doses were 1.4 ± 0.5 and 1.8 ± 0.7 mg/day, respectively. Overall IP of AEs was 11.2%; 90.9% of events were mild. General/injection‐site and gastrointestinal events were most frequent. Medication cost (49.0%) was the predominant factor for dose non‐escalation. At weeks 13 and 26, mean BW loss was −5.7 ± 3.5 and −8.5 ± 5.7 kg (both p < 0.0001; ≥ 5% BW loss in 58.4% and 76.7%) and mean systolic blood pressure decrease was 9.0 ± 16.7 and 10.4 ± 18.9 mmHg, respectively. Conclusion: Liraglutide at < 3.0 mg/day was well‐tolerated, with BW reduction observed over 26 weeks in Taiwanese adults. Medication cost is a barrier to long‐term obesity management and a significant consideration for health policies in Taiwan.